TY - JOUR
T1 - Pharmaceutical care needs of haematology out-patients receiving cytotoxic chemotherapy
AU - Hamill, M.
AU - Dalrymple, H.
AU - Kinnear, M.
PY - 2009/2
Y1 - 2009/2
N2 - Background and objective To identify pharmaceutical care needs in
haematology out-patients receiving cytotoxic chemotherapy through
characterisation of pharmaceutical care issues and seeking opinions
about the pharmaceutical service from patients and healthcare
professionals.
Design Retrospective review of records and categorisation of pharmaceutical
care issues in 24 patients. Semi-structured interviews were
audio-taped with all five haematology consultants, as were two focus
groups with seven nursing staff. Consistent codes were used to analyse
the transcripts into themes. Questionnaires handed to 100
78 Pharm World Sci (2009) 31:40-141
123
haematology patients or carers (41% response) On which they were
asked to select which medicines they received, difficulties encountered
when taking medicines, further medicine information needs and
preferred source, potential services from clinical pharmacists, satisfaction
with current pharmacy service and expected waiting times for
medicines given the safety checks which must be undertaken.
Setting Haematology outpatient clinic within cancer centre of large
teaching hospital.
Main outcome measures Number and type of pharmaceutical care
issues recorded. Opinions of doctors, nurses and patients about
pharmaceutical service needs.
Results The mean (SD) age was 69 (11.8) years and 17 (71%) were
male. Review of patients with; chronic lymphocytic leukaemia,
chronic myeloid leukaemia, acute myeloid leukaemia, essential
thrombocythaemia, polycythaemia vera, non-hodgkin's lymphoma
and multiple myeloma identified 241 pharmaceutical care issues as
potential drug related problems, of which 172 (71%) addressed
adverse drug reactions, 30 (12%) identified additional medication
needs, 24 (10%) identified unnecessary medication use, 9 (4%)
identified doses suspected of being too low, 4 (2%) identified doses
suspected of being too high and 2 (1%) concerned prescription of an
ineffective drug. Checks or patient monitoring issues were largely due
to safety enquiries (75%) and also included medication needs enquiries
(22%) and effectiveness enquiries (3%).
Most patients reported satisfaction with the pharmacy service, 4
(10%) had unrealistic expectations of waiting \15 min for their
prescription. Healthcare professionals reported the need for better
team education, communication and systems to target patients
receiving complex regimens and those who are elderly and easily
confused. Patients (29%) reported problems with compliance which
was confirmed by nurses. Proposed solutions to patient waiting times
identified doctors' and nurses' lack of awareness of guidelines for the
safe dispensing of chemotherapy.
Conclusions The care issues confirmed that patients are at risk of
adverse drug reactions and interactions between medicines for comorbidities
and their chemotherapy. Pharmaceutical care should
address these care issues, identify the need for supportive therapy and
confirm chemotherapy doses to minimise clinical risk. Improved
communication and referral systems are required and educational
needs of patients and healthcare professionals have been identified
and will be addressed in development of the pharmacy service to meet
patient need.
AB - Background and objective To identify pharmaceutical care needs in
haematology out-patients receiving cytotoxic chemotherapy through
characterisation of pharmaceutical care issues and seeking opinions
about the pharmaceutical service from patients and healthcare
professionals.
Design Retrospective review of records and categorisation of pharmaceutical
care issues in 24 patients. Semi-structured interviews were
audio-taped with all five haematology consultants, as were two focus
groups with seven nursing staff. Consistent codes were used to analyse
the transcripts into themes. Questionnaires handed to 100
78 Pharm World Sci (2009) 31:40-141
123
haematology patients or carers (41% response) On which they were
asked to select which medicines they received, difficulties encountered
when taking medicines, further medicine information needs and
preferred source, potential services from clinical pharmacists, satisfaction
with current pharmacy service and expected waiting times for
medicines given the safety checks which must be undertaken.
Setting Haematology outpatient clinic within cancer centre of large
teaching hospital.
Main outcome measures Number and type of pharmaceutical care
issues recorded. Opinions of doctors, nurses and patients about
pharmaceutical service needs.
Results The mean (SD) age was 69 (11.8) years and 17 (71%) were
male. Review of patients with; chronic lymphocytic leukaemia,
chronic myeloid leukaemia, acute myeloid leukaemia, essential
thrombocythaemia, polycythaemia vera, non-hodgkin's lymphoma
and multiple myeloma identified 241 pharmaceutical care issues as
potential drug related problems, of which 172 (71%) addressed
adverse drug reactions, 30 (12%) identified additional medication
needs, 24 (10%) identified unnecessary medication use, 9 (4%)
identified doses suspected of being too low, 4 (2%) identified doses
suspected of being too high and 2 (1%) concerned prescription of an
ineffective drug. Checks or patient monitoring issues were largely due
to safety enquiries (75%) and also included medication needs enquiries
(22%) and effectiveness enquiries (3%).
Most patients reported satisfaction with the pharmacy service, 4
(10%) had unrealistic expectations of waiting \15 min for their
prescription. Healthcare professionals reported the need for better
team education, communication and systems to target patients
receiving complex regimens and those who are elderly and easily
confused. Patients (29%) reported problems with compliance which
was confirmed by nurses. Proposed solutions to patient waiting times
identified doctors' and nurses' lack of awareness of guidelines for the
safe dispensing of chemotherapy.
Conclusions The care issues confirmed that patients are at risk of
adverse drug reactions and interactions between medicines for comorbidities
and their chemotherapy. Pharmaceutical care should
address these care issues, identify the need for supportive therapy and
confirm chemotherapy doses to minimise clinical risk. Improved
communication and referral systems are required and educational
needs of patients and healthcare professionals have been identified
and will be addressed in development of the pharmacy service to meet
patient need.
KW - haematology
KW - pharmaceutical care
UR - http://dx.doi.org/10.1007/s11096-008-9262-z
U2 - 10.1007/s11096-008-9262-z
DO - 10.1007/s11096-008-9262-z
M3 - Article
SN - 0928-1231
VL - 31
SP - 78
EP - 79
JO - Pharmacy World and Science
JF - Pharmacy World and Science
IS - 1
ER -